Stay updated on Sabatolimab in HMA for Higher Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page.

Latest updates to the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page
- Check5 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2, indicating a new release; the Back to Top link was removed. No other core content changes detected.SummaryDifference0.6%
- Check12 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.6%
- Check19 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while several location-related terms have been removed.SummaryDifference29%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check41 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check48 days agoChange DetectedThe page has been updated to reflect a lack of efficacy in a specific program and has been revised to a new version. Additionally, a future date of July 31, 2025, has been added.SummaryDifference8%
Stay in the know with updates to Sabatolimab in HMA for Higher Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page.